DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO).
In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek.
"Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, CEO of DaVita. "Jess brings fresh energy and innovative ideas to the CPO role, driving initiatives to attract and retain top talent while maintaining DaVita's status as an employer of choice. We're thrilled to welcome her aboard."
Before joining DaVita, Hergenreter spent 13 years at Vail Resorts, where she excelled in various leadership roles, from HR business partner to Chief of Staff to the CEO. Most recently, she led talent strategies that shaped the experience for 55,000 Vail Resorts employees, focusing on talent acquisition, development, and fostering a culture of diversity and inclusion. Earlier in her career, she provided HR consulting for a diverse range of clients, honing her expertise across industries.
"Having lived and worked in Denver for decades, I've always admired DaVita's distinctive culture," Hergenreter remarked. "I'm honored to step into the role of CPO and look forward to continuing to support an inclusive environment that champions diversity and belonging."
To learn more about DaVita and its leadership, visit DaVita.com/About.
About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of June 30, 2024, DaVita served approximately 265,100 patients at 3,124 outpatient dialysis centers, of which 2,672 centers were located in the United States and 452 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
Media Contacts:
DaVita Newsroom
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$151.85 |
Daily Change: | 4.31 2.92 |
Daily Volume: | 1,494,131 |
Market Cap: | US$12.450B |
October 29, 2024 October 23, 2024 September 13, 2024 August 06, 2024 May 02, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB